--- title: "A $286 million bet on brainwaves: inside China's non-invasive BCI unicorn" date: 2026-10-04 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-bci-brainco-noninvasive-ipo language: en --- # A $286 million bet on brainwaves: inside China's non-invasive BCI unicorn > BrainCo (强脑科技), the Hangzhou neurotechnology company spun out of Harvard, closed a ≈ US$286 million round and filed confidentially for a Hong Kong IPO — a test of whether non-invasive brain–computer interface (脑机接口) can scale commercially. A child who cannot sit still puts on a thin headband. A man who lost his arm below the shoulder closes a prosthetic hand by thinking about closing it. Neither patient underwent brain surgery. The same company built both devices, and this year the company went looking for a public market. BrainCo (强脑科技) is not the most famous name in brain–computer interface (脑机接口), but it may be the closest to proving the technology can pay its own bills. ## From a Harvard lab to Hangzhou BrainCo was founded in 2015 by Bicheng Han (韩璧丞) while he was a doctoral student at Harvard University's Center for Brain Science. It was incubated at the Harvard Innovation Labs, and its first office was in Somerville, Massachusetts. In 2018 the company moved its headquarters to Hangzhou, Zhejiang, while keeping a U.S. office — a typical path for a China-founded, globally-schooled deep-tech startup. Its Chinese entity is Zhejiang Qiangnao Technology Co., Ltd. (浙江强脑科技有限公司). Locally, BrainCo is counted among Hangzhou's "Six Little Dragons" (六小龙) — the city's prized cohort of frontier-tech firms that also includes the AI lab DeepSeek and the robot maker Unitree. ## The bet: non-invasive, not surgical Where Elon Musk's Neuralink and several Chinese peers chase invasive implants threaded into brain tissue, BrainCo bet on the opposite end of the spectrum. Its products read signals from outside the skull — electroencephalography (EEG) and muscle activity — and translate them into control commands or neurofeedback. The flagship is the **BrainRobotics intelligent bionic prosthetic hand**. It fuses brain–computer interface sensing with EMG (muscle) signals and AI algorithms, letting upper-limb amputees move individual fingers. It received U.S. FDA certification on 7 November 2022 and was named one of Time's best inventions in 2019. The company also sells lower-limb bionic products and a focus/relaxation headband line (Focus, later rebranded FocusCalm), plus sleep devices such as Eassleep (深海豚), released the same month as the prosthetic's FDA clearance, and OxyZen in October 2024. The non-invasive choice is a trade-off. Outside-the-skull signals are noisier and lower-bandwidth than implanted ones. But they avoid surgery, scale to consumer volumes, and clear a very different regulatory bar — which is exactly the point. ## The money: a record round, then an IPO In January 2026, BrainCo closed a financing round of **≈ US$286 million (about ¥2 billion)**, co-led by IDG Capital and Walden International — the investment firm founded by former Intel CEO Lip-Bu Tan. The round valued the company above **US$1.3 billion (≈ ¥9.2 billion)**. Industry trackers described it as the world's second-largest single brain–computer interface financing to date, behind only Neuralink's US$650 million Series E in mid-2025. Days earlier, on 3 January 2026, BrainCo had confidentially filed for an initial public offering on the Hong Kong Stock Exchange, working with China International Capital Corporation and UBS. Public filings described a plan for roughly **1.2 billion shares at HK$5–7 per share** (about US$0.64–0.90 each), with a pricing window targeted for March–April 2026. As of late May 2026 the listing had not yet been publicly priced. If it lists, BrainCo would become one of the first brain–computer interface pure-plays to reach a major exchange — a marker investors will watch regardless of sector. ## Why profitability matters here Most brain–computer interface companies live on venture capital while their implants crawl through trials. BrainCo's edge is that it already sells. The company reported its **first full-year profitability in 2025**, driven primarily by consumer-facing products rather than waiting on hospital approvals. That is the core thesis: non-invasive devices can reach paying customers — clinics, individuals, schools — years before an invasive implant clears a multi-year clinical and regulatory gauntlet. Revenue today de-risks the long road to medical-grade products tomorrow. ## A public-interest twist In May 2026, BrainCo (under its Qiangnao entity) launched a Smart Prosthetics Programme with Hong Kong Polytechnic University and the Hong Kong Special Administrative Region Government, providing free smart bionic limbs to **60 Hong Kong amputees** using its non-invasive brain–computer interface technology. It is a reminder that a consumer-scale neurotech company can also sit inside public-health delivery, not just retail shelves. ## Honest limitations This article describes corporate financing and product strategy, not clinical efficacy. The US$286 million figure and the Hong Kong IPO plan are drawn from the company, specialized BCI directories, and Wikipedia/company-records aggregators; the IPO had not priced as of the reporting cutoff, so share terms may change. BrainCo's early attention-headband drew real privacy criticism in Chinese schools (2019), and the company later rebranded that line — a reputational footnote worth holding in view. "Non-invasive" does not mean "clinically validated for every claim," and consumer shipments are not the same as regulatory clearance for disease treatment. I have not assessed BrainCo's competitive position against invasive rivals on signal quality or long-term medical value. ## What readers can do now - **If you track neurotech IPOs:** watch the BrainCo Hong Kong listing as a benchmark — its valuation and post-listing performance will signal whether public markets price non-invasive brain–computer interface as a consumer-electronics business or a medical one. - **If you build or buy assistive tech:** non-invasive bionic limbs with EEG/EMG control are shippable today; compare them on FDA/regulatory certification, battery life, and individual-finger dexterity rather than marketing language. - **If you study the China–US divide:** use BrainCo (non-invasive, commercial) and Neuralink (invasive, clinical) as the two poles of one strategic question — which interface type reaches scale first, and at what medical cost. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-bci-brainco-noninvasive-ipo Free to quote with attribution and a link to the original.